The management of psychotic spectrum disorders, such as schizophrenia, is a complex and long-term process that requires a comprehensive, patient-centered approach. Pharmacists are integral members of the healthcare team, responsible for optimizing pharmacotherapy, managing side effects, and promoting adherence to improve a patient’s quality of life. This quiz will test your knowledge on the evidence-based management strategies for these challenging but treatable conditions.
1. What is the first-line pharmacologic treatment for a first episode of psychosis?
- a. A first-generation (“typical”) antipsychotic
- a. A second-generation (“atypical”) antipsychotic
- c. A long-acting injectable antipsychotic
- d. A combination of two antipsychotics
Answer: b. A second-generation (“atypical”) antipsychotic
2. The primary goal of the acute phase of treatment for schizophrenia is to:
- a. Cure the disease.
- b. Reduce acute, severe positive symptoms like hallucinations and agitation.
- c. Eliminate all negative symptoms.
- d. Find the highest tolerable dose of medication.
Answer: b. To reduce acute, severe positive symptoms like hallucinations and agitation.
3. A patient who fails to respond adequately to trials of at least two different antipsychotics may be considered a candidate for which highly effective agent?
- a. Haloperidol
- b. Aripiprazole
- c. Clozapine
- d. Lurasidone
Answer: c. Clozapine
4. A patient on an atypical antipsychotic complains of weight gain. In addition to counseling on diet and exercise, what is a potential medication management strategy?
- a. Increasing the dose of the current antipsychotic.
- b. Adding a second antipsychotic.
- c. Switching to an agent with a lower risk of metabolic side effects, like aripiprazole or ziprasidone.
- d. Adding metformin to the regimen.
Answer: c. Switching to an agent with a lower risk of metabolic side effects, like aripiprazole or ziprasidone.
5. Long-acting injectable (LAI) antipsychotics are a key management strategy for which common problem in schizophrenia?
- a. Acute agitation
- b. Medication non-adherence
- c. Metabolic side effects
- d. Drug-induced parkinsonism
Answer: b. Medication non-adherence
6. A patient on haloperidol develops a shuffling gait and resting tremor. This can be managed with:
- a. An increase in the haloperidol dose.
- b. The addition of an anticholinergic agent like benztropine.
- c. A switch to another high-potency first-generation agent.
- d. The addition of levodopa.
Answer: b. The addition of an anticholinergic agent like benztropine.
7. Which of the following is NOT a primary goal of the stabilization and maintenance phases of schizophrenia treatment?
- a. To prevent relapse.
- b. To improve social and occupational functioning.
- c. To minimize medication side effects.
- d. To discontinue all antipsychotic medication.
Answer: d. To discontinue all antipsychotic medication.
8. The choice between different second-generation antipsychotics is often based on:
- a. The patient’s side effect tolerance profile.
- b. The medication’s side effect profile.
- c. The patient’s prior response to treatment.
- d. All of the above.
Answer: d. All of the above.
9. What is a key non-pharmacologic intervention that is a crucial part of a comprehensive schizophrenia treatment plan?
- a. A high-fat diet.
- b. Social isolation.
- c. Psychoeducation for the patient and family.
- d. Strenuous, high-intensity exercise.
Answer: c. Psychoeducation for the patient and family.
10. A pharmacist’s role in the management of psychotic disorders includes:
- a. Counseling on the importance of adherence.
- b. Monitoring for and managing side effects.
- c. Educating patients and caregivers about their medications.
- d. All of the above.
Answer: d. All of the above.
11. A patient on clozapine must have which lab parameter monitored regularly due to the risk of agranulocytosis?
- a. Serum creatinine
- b. Liver function tests
- c. Absolute Neutrophil Count (ANC)
- d. Fasting lipid panel
Answer: c. Absolute Neutrophil Count (ANC)
12. A patient complains of severe inner restlessness and an inability to sit still. This side effect, akathisia, can be managed with:
- a. An increase in the antipsychotic dose.
- b. A beta-blocker like propranolol.
- c. An anticholinergic agent.
- d. An antidepressant.
Answer: b. A beta-blocker like propranolol.
13. Assertive Community Treatment (ACT) is an evidence-based, team-based model of care for patients with severe mental illness.
- a. True
- b. False
Answer: a. True
14. A patient develops tardive dyskinesia (TD). The first step in management is:
- a. To increase the dose of the antipsychotic.
- b. To evaluate the possibility of switching to an agent with a lower risk of TD, like clozapine, or adding a VMAT2 inhibitor.
- c. To add an anticholinergic agent.
- d. To reassure the patient that it is a harmless side effect.
Answer: b. To evaluate the possibility of switching to an agent with a lower risk of TD, like clozapine, or adding a VMAT2 inhibitor.
15. A pharmacist counseling a patient starting an antipsychotic should discuss:
- a. The expected timeline for symptom improvement.
- b. The importance of not stopping the medication abruptly.
- c. Key side effects to monitor for.
- d. All of the above.
Answer: d. All of the above.
16. Which of the following is NOT a goal of managing an acute psychotic episode?
- a. To ensure the safety of the patient and others.
- b. To reduce the severity of psychosis and agitation.
- c. To develop a long-term therapeutic alliance.
- d. To immediately start a long-acting injectable medication.
Answer: d. To immediately start a long-acting injectable medication.
17. The management of psychotic disorders is a complex, long-term process that often requires treatment adjustments over time.
- a. True
- b. False
Answer: a. True
18. A key to managing metabolic side effects from atypical antipsychotics is:
- a. Regular monitoring of weight, glucose, and lipids.
- b. Counseling on a healthy diet and exercise.
- c. Both a and b.
- d. Neither a nor b, as these side effects cannot be managed.
Answer: c. Both a and b.
19. A patient is being switched from oral risperidone to its long-acting injectable formulation. A key management point is:
- a. No oral overlap is needed.
- b. The patient must continue the oral antipsychotic for several weeks after the first injection.
- c. The injectable form has fewer side effects.
- d. The dose of the injection is the same as the oral dose.
Answer: b. The patient must continue the oral antipsychotic for several weeks after the first injection.
20. The primary reason for medication non-adherence in schizophrenia is often:
- a. High cost of medication.
- b. Troublesome side effects.
- c. The patient’s lack of insight into their illness.
- d. All of the above are major contributors.
Answer: d. All of the above are major contributors.
21. “Shared decision-making” in schizophrenia treatment involves:
- a. The physician making all the decisions.
- b. A collaborative process where the clinician and patient (and often family) work together to choose a treatment plan.
- c. The pharmacist choosing the medication for the patient.
- d. The patient making all decisions without clinical input.
Answer: b. A collaborative process where the clinician and patient (and often family) work together to choose a treatment plan.
22. A patient with a first episode of psychosis should generally be treated for how long after remission is achieved?
- a. 1 month
- b. 6 months
- c. At least 1-2 years
- d. Indefinitely
Answer: c. At least 1-2 years
23. A key part of managing a patient on clozapine is monitoring for:
- a. Myocarditis
- b. Seizures
- c. Severe constipation
- d. All of the above
Answer: d. All of the above
24. The management of psychotic disorders requires a team-based approach, including pharmacists, physicians, therapists, and case managers.
- a. True
- b. False
Answer: a. True
25. A pharmacist’s role in managing these disorders is crucial for:
- a. Improving adherence.
- b. Minimizing adverse effects.
- c. Improving patient safety and quality of life.
- d. All of the above.
Answer: d. All of the above.
26. Which of the following is NOT a first-line treatment for schizophrenia?
- a. Risperidone
- b. Olanzapine
- c. Aripiprazole
- d. A benzodiazepine as monotherapy.
Answer: d. A benzodiazepine as monotherapy.
27. A patient on an antipsychotic develops hyperprolactinemia. This can lead to what symptoms?
- a. Gynecomastia and galactorrhea
- b. Hypertension
- c. Weight loss
- d. Insomnia
Answer: a. Gynecomastia and galactorrhea
28. Which antipsychotic has a particularly high risk for causing hyperprolactinemia?
- a. Aripiprazole
- b. Quetiapine
- c. Risperidone
- d. Clozapine
Answer: c. Risperidone
29. The overall goal of maintenance therapy is:
- a. Relapse prevention.
- b. To use the highest tolerated dose.
- c. To use at least three different antipsychotics.
- d. To cure the disease.
Answer: a. Relapse prevention.
30. A key component of managing a patient with schizophrenia is addressing comorbid:
- a. Substance use disorders.
- b. Cardiovascular disease.
- c. Diabetes.
- d. All of the above.
Answer: d. All of the above.
31. Smoking can induce the metabolism of which antipsychotic, potentially requiring higher doses?
- a. Risperidone
- b. Haloperidol
- c. Olanzapine
- d. Aripiprazole
Answer: c. Olanzapine
32. The management of a first psychotic episode should include:
- a. A focus on minimizing the duration of untreated psychosis.
- b. A low starting dose of a second-generation antipsychotic.
- c. Extensive psychoeducation for the patient and family.
- d. All of the above.
Answer: d. All of the above.
33. The management of psychotic disorders is a lifelong process for most patients.
- a. True
- b. False
Answer: a. True
34. The use of Cognitive Behavioral Therapy for psychosis (CBTp) is an evidence-based non-pharmacologic intervention.
- a. True
- b. False
Answer: a. True
35. A pharmacist counseling on a long-acting injectable should ensure the patient understands:
- a. The injection schedule.
- b. That they must come to the clinic for their injection.
- c. The potential for injection site reactions.
- d. All of the above.
Answer: d. All of the above.
36. A patient with schizophrenia should be monitored for which of the following?
- a. Positive symptoms
- b. Negative symptoms
- c. Medication side effects
- d. All of the above
Answer: d. All of the above
37. A key challenge in the management of schizophrenia is the treatment of:
- a. Positive symptoms, as they respond poorly to medication.
- b. Negative and cognitive symptoms, as they respond poorly to currently available medications.
- c. Agitation.
- d. Hallucinations.
Answer: b. Negative and cognitive symptoms, as they respond poorly to currently available medications.
38. The use of a standardized rating scale, like the PANSS, is helpful for:
- a. Diagnosing schizophrenia.
- b. Objectively monitoring the severity of symptoms over time.
- c. Choosing an antipsychotic.
- d. Predicting relapse.
Answer: b. Objectively monitoring the severity of symptoms over time.
39. A pharmacist can help manage metabolic syndrome by:
- a. Counseling on diet and exercise.
- b. Advocating for a switch to a metabolically friendlier agent if appropriate.
- c. Monitoring lab values like glucose and lipids.
- d. All of the above.
Answer: d. All of the above.
40. The management of schizophrenia requires a recovery-oriented approach.
- a. True
- b. False
Answer: a. True
41. Which of the following is NOT a primary goal of schizophrenia management?
- a. To reduce or eliminate symptoms.
- b. To improve social and occupational functioning.
- c. To achieve a complete cure and cessation of all therapy.
- d. To minimize adverse effects.
Answer: c. To achieve a complete cure and cessation of all therapy.
42. A patient is stable on their antipsychotic medication. The pharmacist’s role includes:
- a. Encouraging continued adherence.
- b. Ongoing monitoring for long-term side effects like tardive dyskinesia.
- c. Both a and b.
- d. Recommending the patient stop their medication.
Answer: c. Both a and b.
43. A pharmacist’s role includes identifying medications that can induce or worsen psychosis.
- a. True
- b. False
Answer: a. True
44. What is a key reason to prefer a second-generation antipsychotic over a first-generation one for a first episode?
- a. They are more effective.
- b. They have a lower risk of causing acute and long-term motor side effects, which can improve adherence.
- c. They are cheaper.
- d. They work faster.
Answer: b. They have a lower risk of causing acute and long-term motor side effects, which can improve adherence.
45. Which of the following is NOT a good counseling point for a patient on an antipsychotic?
- a. “This medication is not addictive, but you should not stop it suddenly.”
- b. “It’s important to take this every day to prevent your symptoms from coming back.”
- c. “You will be cured in 6 months and can stop this medication.”
- d. “Let’s talk about some side effects to watch out for, like feeling drowsy or dizzy.”
Answer: c. “You will be cured in 6 months and can stop this medication.”
46. The management of psychotic disorders often involves treating comorbid conditions like:
- a. Cardiovascular disease
- b. Diabetes
- c. Substance use disorders
- d. All of the above
Answer: d. All of the above
47. A pharmacist helping a patient enroll in a patient assistance program for their long-acting injectable is addressing what barrier to care?
- a. Side effects
- b. Adherence
- c. Stigma
- d. Cost
Answer: d. Cost
48. A key aspect of managing these disorders is building a strong therapeutic alliance with the patient and their caregivers.
- a. True
- b. False
Answer: a. True
49. The overall management of a psychotic spectrum disorder is a:
- a. Short-term, curative process.
- b. Long-term, collaborative process focused on recovery and quality of life.
- c. Process that only involves medication.
- d. Process that is the same for every patient.
Answer: b. Long-term, collaborative process focused on recovery and quality of life.
50. The ultimate goal of learning about the management of psychotic disorders is to:
- a. Be able to provide safe, effective, evidence-based, and compassionate care for a vulnerable patient population.
- b. Pass the psychiatry exam.
- c. Memorize all the antipsychotic side effects.
- d. Be able to diagnose schizophrenia.
Answer: a. Be able to provide safe, effective, evidence-based, and compassionate care for a vulnerable patient population.
